HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

Pratistha Koirala, Michael E. Roth, Jonathan Gill, Jordan M. Chinai, Michelle R. Ewart, Sajida Piperdi, David S. Geller, Bang H. Hoang, Yekaterina V. Fatakhova, Maya Ghorpade, Xingxing Zang, Richard Gorlick

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.

Original languageEnglish (US)
Article number31154
JournalScientific Reports
Volume6
DOIs
StatePublished - Aug 17 2016

Fingerprint

Osteosarcoma
Neoplasm Metastasis
Survival
Tumor-Infiltrating Lymphocytes
Disease-Free Survival
Tumor Microenvironment
Immunosuppressive Agents
Neoplasms
T-Lymphocytes
Proteins

ASJC Scopus subject areas

  • General

Cite this

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. / Koirala, Pratistha; Roth, Michael E.; Gill, Jonathan; Chinai, Jordan M.; Ewart, Michelle R.; Piperdi, Sajida; Geller, David S.; Hoang, Bang H.; Fatakhova, Yekaterina V.; Ghorpade, Maya; Zang, Xingxing; Gorlick, Richard.

In: Scientific Reports, Vol. 6, 31154, 17.08.2016.

Research output: Contribution to journalArticle

Koirala, Pratistha ; Roth, Michael E. ; Gill, Jonathan ; Chinai, Jordan M. ; Ewart, Michelle R. ; Piperdi, Sajida ; Geller, David S. ; Hoang, Bang H. ; Fatakhova, Yekaterina V. ; Ghorpade, Maya ; Zang, Xingxing ; Gorlick, Richard. / HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. In: Scientific Reports. 2016 ; Vol. 6.
@article{b518e5137d784ffa80ba272f3cb1812f,
title = "HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival",
abstract = "Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68{\%} of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93{\%} vs 53{\%}, p = 0.02). TILs were present in 75{\%} of all osteosarcoma specimens. Patients whose tumors were ≥25{\%} or ≥50{\%} HHLA2 positive had significantly worse five-year event-free-survival (33{\%} vs 64{\%}, p = 0.03 and 14{\%} vs 59{\%}, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.",
author = "Pratistha Koirala and Roth, {Michael E.} and Jonathan Gill and Chinai, {Jordan M.} and Ewart, {Michelle R.} and Sajida Piperdi and Geller, {David S.} and Hoang, {Bang H.} and Fatakhova, {Yekaterina V.} and Maya Ghorpade and Xingxing Zang and Richard Gorlick",
year = "2016",
month = "8",
day = "17",
doi = "10.1038/srep31154",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

AU - Koirala, Pratistha

AU - Roth, Michael E.

AU - Gill, Jonathan

AU - Chinai, Jordan M.

AU - Ewart, Michelle R.

AU - Piperdi, Sajida

AU - Geller, David S.

AU - Hoang, Bang H.

AU - Fatakhova, Yekaterina V.

AU - Ghorpade, Maya

AU - Zang, Xingxing

AU - Gorlick, Richard

PY - 2016/8/17

Y1 - 2016/8/17

N2 - Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.

AB - Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=84982182391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982182391&partnerID=8YFLogxK

U2 - 10.1038/srep31154

DO - 10.1038/srep31154

M3 - Article

C2 - 27531281

AN - SCOPUS:84982182391

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 31154

ER -